Literature DB >> 21721101

Targeted therapeutics and nanodevices for vascular drug delivery: quo vadis?

Vladimir R Muzykantov1.   

Abstract

This issue of the journal is dedicated to targeted delivery of therapeutics in the vasculature, an approach that holds promise to optimize treatment of diverse pathological conditions ranging from ischemia and tumor growth to metabolic and genetic diseases. From the standpoint of drug delivery, circulation system represents the natural route to the targets, whereas its components (blood and vascular cells) represent targets, carriers or barriers for drug delivery. Diverse nanodevices and targeted therapeutic agents that are designed and tested in animal and early clinical studies to achieve optimal and precise spatiotemporal control of the pharmacokinetics, destination, metabolism and effect of pharmacological agents will be discussed in this introductory essay and subsequent critical reviews in this series.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21721101      PMCID: PMC3342817          DOI: 10.1002/iub.480

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  12 in total

1.  Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting.

Authors:  S M Danilov; V D Gavrilyuk; F E Franke; K Pauls; D W Harshaw; T D McDonald; D J Miletich; V R Muzykantov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

2.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.

Authors:  Juan-Carlos Murciano; Sandra Medinilla; Donald Eslin; Elena Atochina; Douglas B Cines; Vladimir R Muzykantov
Journal:  Nat Biotechnol       Date:  2003-07-06       Impact factor: 54.908

Review 3.  Biomedical aspects of targeted delivery of drugs to pulmonary endothelium.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2005-09       Impact factor: 6.648

4.  Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung.

Authors:  Phil Oh; Per Borgström; Halina Witkiewicz; Yan Li; Bengt J Borgström; Adrian Chrastina; Koji Iwata; Kurt R Zinn; Richard Baldwin; Jacqueline E Testa; Jan E Schnitzer
Journal:  Nat Biotechnol       Date:  2007-03-04       Impact factor: 54.908

5.  Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies.

Authors:  M Magnani; L Rossi; G Brandi; G F Schiavano; M Montroni; G Piedimonte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

6.  Targeting the prostate for destruction through a vascular address.

Authors:  Wadih Arap; Wolfgang Haedicke; Michele Bernasconi; Renate Kain; Daniel Rajotte; Stanislaw Krajewski; H Michael Ellerby; Dale E Bredesen; Renata Pasqualini; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

7.  A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1.

Authors:  Silvia Muro; Rainer Wiewrodt; Anu Thomas; Lauren Koniaris; Steven M Albelda; Vladimir R Muzykantov; Michael Koval
Journal:  J Cell Sci       Date:  2003-04-15       Impact factor: 5.285

Review 8.  Polymeric carriers: role of geometry in drug delivery.

Authors:  Eric A Simone; Thomas D Dziubla; Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

9.  Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy.

Authors:  Phil Oh; Yan Li; Jingyi Yu; Eberhard Durr; Karolina M Krasinska; Lucy A Carver; Jacqueline E Testa; Jan E Schnitzer
Journal:  Nature       Date:  2004-06-10       Impact factor: 49.962

10.  Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Nankang Hong; Juan-Carlos Murciano; Kumkum Ganguly; Claudia Gottstein; Melpo Christofidou-Solomidou; Steven M Albelda; Aron B Fisher; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2007-11-28       Impact factor: 22.113

View more
  6 in total

1.  Global diffusion limitations during the initial phase of the formation of a protein corona around nanoparticles.

Authors:  Vladimir P Zhdanov
Journal:  J Biol Phys       Date:  2019-03-20       Impact factor: 1.365

Review 2.  Targeting therapeutics to endothelium: are we there yet?

Authors:  Raisa Yu Kiseleva; Patrick M Glassman; Colin F Greineder; Elizabeth D Hood; Vladimir V Shuvaev; Vladimir R Muzykantov
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

Review 3.  Vascular Inflammation: A Novel Access Route for Nanomedicine.

Authors:  Roberto Molinaro; Christian Boada; Guillermo Medrano Del Rosal; Kelly A Hartman; Claudia Corbo; Elizabeth D Andrews; Naama E Toledano-Furman; John P Cooke; Ennio Tasciotti
Journal:  Methodist Debakey Cardiovasc J       Date:  2016-09

Review 4.  Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.

Authors:  Melissa Howard; Blaine J Zern; Aaron C Anselmo; Vladimir V Shuvaev; Samir Mitragotri; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2014-05-07       Impact factor: 15.881

5.  The new frontiers of the targeted interventions in the pulmonary vasculature: precision and safety (2017 Grover Conference Series).

Authors:  Jacob S Brenner; Raisa Yu Kiseleva; Patrick M Glassman; Hamideh Parhiz; Colin F Greineder; Elizabeth D Hood; Vladimir V Shuvaev; Vladimir R Muzykantov
Journal:  Pulm Circ       Date:  2017-12-20       Impact factor: 3.017

6.  ICAM-1-Targeted Nanocarriers Attenuate Endothelial Release of Soluble ICAM-1, an Inflammatory Regulator.

Authors:  Rachel L Manthe; Silvia Muro
Journal:  Bioeng Transl Med       Date:  2017-01-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.